Provention Bio: Sanofi Acquires Diabetes Drug Via Provention Buyout

Sanofi SA, the renowned French drugmaker, has announced its plans to shell out a staggering $2.9 billion to acquire the biotech firm Provention Bio. The purchase decision comes off the back of an existing co-marketing deal between the two pharma companies. The acquisition, expected to finalize in Q2 of 2023, would grant Sanofi full ownership [...]The post Sanofi Acquires Diabetes Drug Via Provention Buyout appeared first on Healthcare Weekly.